Global
Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin
Lymphoma Market Research Report provides an overview of the Non-Hodgkin
Lymphoma (Oncology) pipeline landscape.
Non-Hodgkin lymphoma (also known as non-Hodgkin's
lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells
called lymphocytes, which are part of the body's immune system. Symptoms depend
on what area of the body is affected by the cancer and how fast the cancer is
growing. Symptoms may include night sweats (soaking the bed sheets and pajamas
even though the room temperature is not too hot),fever and chills that come and
go, itching, swollen lymph nodes in the neck, underarms, groin, or other areas,
weight loss, coughing or shortness of breath if the cancer affects the thymus
gland or lymph nodes in the chest, putting pressure on the windpipe (trachea)
or other airway, abdominal pain or swelling, leading to loss of appetite,
constipation, nausea, and vomiting and headache, concentration problems,
personality changes, or seizures if the cancer affects the brain. Treatment
includes surgery, radiation therapy and chemotherapy.
Global
Markets Direct's Pharmaceutical and Healthcare latest pipeline guide
Non-Hodgkin Lymphoma - Pipeline Review, H1 2018, provides comprehensive
information on the therapeutics under development for Non-Hodgkin Lymphoma
(Oncology)
The
guide covers the descriptive pharmacological action of the therapeutics, its
complete research and development history and latest news and press releases.
The Non-Hodgkin Lymphoma (Oncology) pipeline guide covers
therapeutics under Development by Companies /Universities /Institutes, the
molecules developed by Companies in Pre-Registration, Filing
rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed,
Preclinical, Discovery and Unknown stages are 10, 4, 30, 160, 136, 1, 5, 126,
15 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase
I, Preclinical and Discovery stages comprises 19, 22, 17 and 4 molecules,
respectively.
Non-Hodgkin Lymphoma (Oncology) pipeline guide helps
in identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage. The guide is built using data
and information sourced from Global Markets Direct's proprietary databases,
company/university websites, clinical trial registries, conferences, SEC
filings, investor presentations and featured press releases from
company/university sites and industry-specific third party sources.
Additionally, various dynamic tracking processes ensure that the most recent
developments are captured on a real time basis.
The pipeline guide provides a snapshot of the
global therapeutic landscape of Non-Hodgkin Lymphoma (Oncology).
-
The pipeline guide reviews pipeline therapeutics for Non-Hodgkin Lymphoma
(Oncology) by companies and universities/research institutes based on
information derived from company and industry-specific sources.
-
The pipeline guide covers pipeline products based on several stages of
development ranging from pre-registration till discovery and undisclosed
stages.
-
The pipeline guide features descriptive drug profiles for the pipeline products
which comprise, product description, descriptive licensing and collaboration
details, R&D brief, MoA & other developmental activities.
-
The pipeline guide reviews key companies involved in Non-Hodgkin Lymphoma
(Oncology) therapeutics and enlists all their major and minor projects.
-
The pipeline guide evaluates Non-Hodgkin Lymphoma (Oncology) therapeutics based
on mechanism of action (MoA), drug target, route of administration (RoA) and
molecule type.
-
The pipeline guide encapsulates all the dormant and discontinued pipeline
projects.
-
The pipeline guide reviews latest news related to pipeline therapeutics for
Non-Hodgkin Lymphoma (Oncology)
Procure strategically important competitor
information, analysis, and insights to formulate effective R&D strategies.
-
Recognize emerging players with potentially strong product portfolio and create
effective counter-strategies to gain competitive advantage.
-
Find and recognize significant and varied types of therapeutics under
development for Non-Hodgkin Lymphoma (Oncology).
-
Classify potential new clients or partners in the target demographic.
-
Develop tactical initiatives by understanding the focus areas of leading
companies.
-
Plan mergers and acquisitions meritoriously by identifying key players and it's
most promising pipeline therapeutics.
-
Formulate corrective measures for pipeline projects by understanding
Non-Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication
therapeutics.
-
Develop and design in-licensing and out-licensing strategies by identifying
prospective partners with the most attractive projects to enhance and expand
business potential and scope.
-
Adjust the therapeutic portfolio by recognizing discontinued projects and
understand from the know-how what drove them from pipeline.
For more
information, click on the link below:
Related Reports:-
Contact Us:-
Ken Research
Ankur Gupta, Head Marketing &
Communications
0124-4230204
No comments:
Post a Comment